Rockefeller Capital Management
EWTX icon

Rockefeller Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Rockefeller Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2K Sell
324
-408
-56% -$14.1K ﹤0.01% 3900
2026
Q1 		$23.1K Buy
732
+550
+302% +$15.9K ﹤0.01% 3649
2025
Q4 		$4.52K Buy
+182
New +$3.65K ﹤0.01% 4104

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rockefeller Capital Management's EWTX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 56% in Q2 2026, selling an estimated $14.1K and leaving 324 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3900.

Rockefeller Capital Management first reported a position in EWTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $23.1K in Q1 2026. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Rockefeller Capital Management held 324 shares of Edgewise Therapeutics worth $13.2K as of Q2 2026.
  • Rockefeller Capital Management sold 408 Edgewise Therapeutics shares in Q2 2026, an estimated $14.1K.
  • Edgewise Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3900 holding.
  • Rockefeller Capital Management first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's Edgewise Therapeutics position peaked at $23.1K in Q1 2026.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.